SCHEDULE 13G/A
Statement of Beneficial Ownership
Xilio Therapeutics, Inc. Filed Acc 0001193125-26-054804
Stakes reported in this filing
| Reporting person | Shares | Of the class |
|---|---|---|
| BCLS II Equity Opportunities, LP | 6,259,742 | 8.5% |
| Bain Capital Life Sciences Fund II, L.P. | 992,111 | 1.3% |
| BCIP Life Sciences Associates, LP | 120,833 | 0.2% |
| BCLS II Investco, LP | 0 | 0% |
Members of a group can each report the same shares, so these rows overlap and don't add up.
Stake history · largest stake in each 13D and 13G
- 2026-11-16 SCHEDULE 13G · ADAR1 Capital Management, LLC 9.3%
- 2026-11-16 SCHEDULE 13G · Logos Global Management LP 9.99%
- 2026-11-13 SCHEDULE 13G/A · Coastlands Capital LP 9.99%
- 2026-11-12 SCHEDULE 13G · Adage Capital Management, L.P. 7.06%
- 2026-08-14 SCHEDULE 13G/A · StemPoint Capital LP 9.5%
- 2026-05-15 SCHEDULE 13G/A · BCLS II Equity Opportunities, LP 9.99%
- 2026-05-15 SCHEDULE 13G · ORBIMED ADVISORS LLC 9.99%
- 2026-05-15 SCHEDULE 13G/A · Point72 Asset Management, L.P. 0%
- 2026-05-15 SCHEDULE 13G · Sirenia Capital Management LP 9.9%
- 2026-02-17 SCHEDULE 13G/A · BCLS II Equity Opportunities, LP 8.5%
- 2026-02-17 SCHEDULE 13G/A · StemPoint Capital LP 8.4%
- 2026-02-13 SCHEDULE 13G/A · Frazier Life Sciences Public Fund, L.P. 6.7%
Loading xslSCHEDULE_13G_X01/primary_doc.xml…